Floatz logo

bi 765049

Digestive System Cancer

Boehringer IngelheimPhase 1Active
CC
44/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
32/ 100
Competitive Position
81/ 100

Competitive context

72 Active assets in the Digestive System Cancer cohort.

Asset / SponsorPhaseRating
(±)-2-(O-CHLOROPHENYL)-2-(METHYLAMINO)CYCLOHEXANONE
Brian Anderson, MD
Phase 4BB
Irinotecan
Amgen
Phase 2BB
FLUOROURACILUM
Alliance for Clinical Trials in Oncology
Phase 2BB
DEXAMETHASONE
Cedars-Sinai Medical Center
Phase 4BB
(±)-1-BUTYL-2',6'-PIPECOLOXYLIDIDE MONOHYDROCHLORIDE
Allegheny Singer Research Institute (also known as Allegheny Health Network Research Institute)
Phase 4BB

View all 50 →

Same molecule, other indications

bi 765049 is also rated in:

Colorectal Neoplasms, Carcinoma, Non-Small-Cell Lung, Pancreatic Neoplasms, Carcinoma, Hepatocellular, Head and Neck Neoplasms, Gastrointestinal NeoplasmsDormant
CC
Indicative ·
47 / 100
View asset →
gastric carcinomaDormant
CC
Indicative ·
43 / 100
View asset →
head and neck cancerDormant
CC
Indicative ·
42 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →